BACKGROUND: Exome and targeted sequencing studies have identified potential driver mutations for a variety of tumor types. Cutaneous squamous cell carcinoma (cSCC) is one of the most highly mutated cancers but typically is associated with low rates of metastasis and high survival rates. Nevertheless, metastatic cSCC is a significant health threat; up to 8800 individuals die each year of this disease. METHODS: Because it is difficult to predict which cSCCs are more likely to metastasize, and because to the best of the authors' knowledge there are no targeted therapies specifically designated for patients with metastatic cSCC, exome and/or targeted sequencing of 18 metastatic and 10 primary cSCCs was performed to identify mutations that were more frequent in metastatic tumors and might be targeted for therapeutic benefit. The authors compared their results with published sequencing results of an additional 223 primary tumors and 68 metastatic cSCCs. RESULTS: The authors identified genes demonstrating higher mutation frequencies in metastatic cSCC compared with primary tumors, including the chromatin remodeling gene lysine methyltransferase 2D (KMT2D) and the classic skin tumor suppressor tumor protein p53 (TP53), which was found to be mutated in 54% of primary tumors compared with 85% of metastatic tumors (P<.0001). CONCLUSIONS: These studies appear to uncover potential pathways that are important in metastatic cSCC and that broaden understanding of the biology contributing to aggressive tumor behavior. These results may lead to new therapeutic strategies. Cancer 2017;123:1184-93. V C 2016 American Cancer Society.
INTRODUCTION
Although only a small percentage of cutaneous squamous cell carcinomas (cSCCs) metastasize, approximately 3900 to 8800 individuals in the United States die of metastatic cSCC each year. 1 Known predictors of metastasis include disease recurrence; tumors arising in scars; thickness >6 mm; poor differentiation; perineural invasion; invasion beyond subcutaneous fat; and anatomic site such as the lip, temple, and ear. [2] [3] [4] [5] Immunosuppressed patients such as transplant recipients have higher rates of metastasis. 4 Treatment efforts are hampered by an inability to predict which lesions are more likely to recur or metastasize because known correlates do not have high specificity for prognosis.
Tumor protein p53 (TP53) was first identified in the 1990s as being frequently mutated in cSCC; to the best of our knowledge, all subsequent exome and targeted deep-sequencing studies to date for cSCC have confirmed this finding. and other NOTCH pathway genes occur in >75% of tumors. [7] [8] [9] More recently, a study of primary cSCCs identified novel mutations in the previously unrecognized kinetochore gene kinetochore-localized astrin/SPAG5-binding protein (KNSTRN) in 19% of cSCCs. 10 In addition to sequencing primary cSCCs, 2 studies have assessed mutation frequencies in patients with metastatic cSCC. 11, 12 Many of the same genes also were found to be mutated. Exome sequencing studies performed for other types of mucosal SCC tumors, including those arising from the esophagus and head and neck, demonstrated that these genes also are mutated in noncutaneous SCCs, thereby suggesting similar pathways leading to tumor development. Due to the similarities of specific genes being mutated across different types of SCC, a "squamousness" mutation profile has been proposed. 13 To identify mutations unique to metastatic cSCCs, we performed exome sequencing studies on metastatic samples from 12 individuals, 6 of whom had primary tumor available for comparative analysis. Furthermore, we performed targeted sequencing studies of an additional 10 primary cSCCs and 6 unrelated metastatic samples. We integrated and combined these data with publicly available exome and targeted deep-sequencing studies in cSCC. Collectively, these studies demonstrate frequently mutated genes and pathways that are more prevalent in patients with metastatic cSCCs. With further validation studies, these may prove to be biomarkers of aggressive disease and potential therapeutic targets.
MATERIALS AND METHODS

Study Participants and Samples
All studies were approved by the Ohio State University Institutional Review Board. For individuals with a diagnosis of metastatic cSCC or primary nonmetastatic cSCC, we collected formalin-fixed, paraffin-embedded tissue samples. Inclusion criteria included being immunocompetent (ie, not a transplant recipient); having sufficient tumor tissue and a source of normal, nontumor DNA; and a pathologist-confirmed primary cSCC of nonlip origin. For targeted sequencing studies, individuals with a diagnosis of primary cSCC were selected from an existing sample collection. Hematoxylin and eosin-stained slides for each sample were reviewed by a pathologist. Areas of normal skin, primary tumor, and metastatic tumor were marked for coring. Tissue cores for tumors were taken from regions with >70% tumor cells and nonnecrotic regions. Tissue DNA was extracted from core needle samples or was taken from macrodissected sections, as described previously.
14 Peripheral blood DNA, when available, was isolated in the Ohio State University Human Genetics Sample Bank.
Whole Exome Library Generation and Sequencing
We successfully generated exome libraries for metastatic samples from 12 individuals along with 6 primary tumors giving rise to the metastatic samples and 2 unrelated primary tumors using the Illumina Nextera Rapid Capture Exome Library Prep kit (Illumina Inc, San Diego, Calif), which captures approximately 37 mega-base pairs (Mb) of coding sequence. Exome libraries were prepared following the Illumina Nextera Rapid Capture Enrichment Guide (Illumina Inc) with the following exceptions. The first polymerase chain reaction (PCR) amplification was increased to 11 cycles. Because our DNA consisted of small fragments, the bead ratio in the first PCR clean-up was changed to 1:1 to eliminate fragments of approximately <175 base pair (bp). This led to a loss of DNA and therefore each sample was run in duplicate and pooled before the first hybridization step. DNAs were barcoded to allow for pooling of 6 to 8 samples per lane. Libraries were sequenced on an Illumina HiSeq 2500 Sequencing System (Illumina Inc) with paired-end 100-bp reads.
Data Analysis Exome Studies
Analyses were first completed on the sets of matched normal DNA, primary tumor, and metastatic samples, focusing on genes shown previously to be highly mutated in primary cSCCs, genes in epigenetic pathways, and genes on panels used for identifying mutations in therapeutic targets. Data processing and analysis included Quality Control (QC) filtering, alignment, variant calling, and variant annotation. For QC filtering, we used FastQC (Babraham Bioinformatics, Cambridge, UK) for the read quality evaluation. We then trimmed adapter sequences on the 3' and 5' ends and filtered based on base quality scores (<20) and nucleotide distributions using Cutadapt Software (TU Dormund, Germany). 15 After preprocessing the sequence reads using a filtering index, we performed sequence alignment to the human reference genome, Grch37 build, using the BurrowsWheeler aligner (version 0.7.5) for paired-end data (Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK). 16 For variant calling, duplicate reads were removed using Picard 1.94 (Broad Institute, Cambridge, Mass). GATK 2.8.1 was used to realign the sequences around the known indels to improve alignment (Broad Institute, Cambridge, Mass).
17 Mutect 1.1.4 software was used to make the variant calling using paired samples (Broad Institute, Cambridge, Mass). 18 Indels were identified using the GATK somatic indel detector (version 1.4) (Broad Institute, Cambridge, Mass). Variant annotation was performed on GenomOncology's GenomAnalytics platform (GenomOncology, Cleveland, Ohio), using Ensembl69 and dbSNP138 databases. The Broad Institute Integrative Genomic Viewer (Broad Institute, Cambridge, Mass) was used to confirm positive findings. Sequencing performance was assessed by measuring the number of reads, mapped reads, target base coverage, and read quality using the Picard HsMetrics tool (Broad Institute, Cambridge, Mass). Somatic exonic variants (inframe, frameshift, nonsense, and missense) were included in mutation counts.
Read cutoff values using the default Mutect read cutoff values were 14 for tumor samples and 8 for normal samples.
Targeted Sequencing and Data Analysis
Targeted sequencing using the Ion AmpliSeq Comprehensive Cancer Panel (Thermo Fisher Scientific, Waltham, Mass), which consists of complete exon coverage for 409 genes from the Wellcome Trust Sanger Institute Cancer Gene Census, was successfully completed on 6 additional metastatic samples plus 1 metastatic sample included in the original exome sequencing studies. In addition, we included paired normal and SCC DNA from 10 individuals with primary, nonmetastatic cSCCs. Quantitative PCR was used to ensure sufficient amplifiable material. Libraries were run on an Ion Proton (Thermo Fisher Scientific).
Analysis for the Ion AmpliSeq Comprehensive Cancer Panel was performed using Thermo Fisher Ion Reporter software (Thermo Fisher Scientific). For paired analyses, normal samples when available were used to filter germline variants. For samples lacking a paired normal sample, variants present in the Single Nucleotide Polymorphism database (dbSNP) with a frequency of >0.1% and variants not in the Catalogue of Somatic Mutations in Cancer (COSMIC) database present at 40% of the reads were eliminated from analyses. Somatic mutations had to be present in 9% of sequence reads with a minimum total read count of 20. Nonsense, missense, and frameshift mutations were included.
Statistical Analysis
A Fisher exact test was used to calculate P values for differences in mutation frequency between primary tumors and metastatic tumors. Hochberg multiple comparisons testing was used to correct for multiple tests. To determine whether any one study was driving the observed differences, we performed a "take one out analysis" for all genes with a P .05.
RESULTS
Participant Demographics for Exome Study
To identify mutations that are present in metastatic cSCCs, we performed exome sequencing on samples from 12 individuals (see Supporting Information Table 1 ). Metastatic samples were taken from a variety of sites, but greater than one-half were obtained from lymph nodes ( Table 1 ). The primary cSCCs giving rise to metastases were most often located on the face or ear (Table 1) . Study participants primarily were men with an average age of 72.3 years at the time of diagnosis (Table 1 ) (see Supporting Information Tables 1 and 2 ). Samples for exome sequencing included 10 formalin-fixed, paraffin-embedded metastatic cSCC DNA samples with a paired germline DNA sample from blood or histologically normal tissue and 2 additional metastatic samples for which normal tissue was unavailable. In addition to metastatic tumors, we also obtained tissue from the primary cSCC believed to be giving rise to the metastasis for 6 of the 12 individuals and independent primary tumors from 2 individuals (see Supporting Information Tables 1 and 2 ).
Identification of Significantly Mutated Genes in Metastatic cSCC
Cancers related to ultraviolet light such as cSCC and melanoma have been reported to have the highest mutational burden of any cancers. 7, 9, 19, 20 After excluding any variants in the dbSNP and synonymous changes, samples in our exome study demonstrated 1 to 135 mutations per Mb sequenced. The average mutation rate was 11.8 mutations per Mb of exomic DNA sequenced after removal of the tumor, with 135 mutations per Mb. The average number of reads per sample was 66 million, with an 82% mapping rate and 93% paired reads (see Supporting Information Table 2 ).
Initial analyses focused on genes previously reported to have been mutated in cSCC and "potentially targetable" genes as found on clinical sequencing panels. As expected, many of the common mutations observed in our samples had been identified in previous studies of cSCC ( Fig. 1) (Table 2 ) (see Supporting Information Table 3) . 1, [7] [8] [9] [10] 12, 21 Of the previously reported genes, TP53 was mutated in 58% and NOTCH pathway genes were mutated in 66% of the metastatic samples, respectively. Cyclin-dependent kinase inhibitor 2A (CDKN2A) was found to be mutated in only 2 of the metastatic samples (17%), which is lower than in previous studies. The current analyses also revealed high mutation rates in epigenetic regulators: lysine methyltransferase 2D (KMT2D) (also called MLL2) was mutated in 8 of 12 metastatic Original Article 
Abbreviations: cSCC, cutaneous squamous cell carcinoma; NA, not applicable; SCC, squamous cell carcinoma; y, years. a Because cSCC that metastasized to multiple sites was counted more than once, the number was greater than the number of tumors. samples (67%) (3 truncating mutations) and lysine acetyltransferase 6A (KAT6A) (also known as MOZ) was mutated in 4 of 12 metastatic samples (33%) (2 truncating mutations). Because both KMT2D and KAT6A are important for epigenetic regulation and histone modifications, we assessed the frequency of mutations in other epigenetic and histone modifiers. Epigenetic genes found to be mutated in the metastatic samples in the current study included lysine methyltransferase 2C (KMT2C) (58%), SET domaincontaining 2 (SETD2) (50%), AT-rich interaction domain 2 (ARID2) (17%), E1A-binding protein P300 (EP300) (33%), lysine methyltransferase 2A (KMT2A) (33%), tet methylcytosine dioxygenase 2 (TET2) (8%), lysine demethylase 6A (KDM6A) (8%), and CREB-binding protein (CREBBP) (17%). A second category of genes exhibiting frequent mutations in our exome study were in DNA repair pathways. From the exome sequencing, 4 of 12 metastatic tumors (33%) were found to have missense mutations in ATR serine/threonine kinase (ATR). Three metastatic tumors (25%) had mutations in Fanconi anemia complementation group D2 (FANCD2), including 1 with a truncating mutation. Other DNA repair genes demonstrating mutation frequencies of >10% include Bloom syndrome RecQ helicase-like (BLM) (17%) and ATM serine/threonine kinase (ATM) (25%). Additional cancer-related genes found to be mutated in the metastatic samples included phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG), FAT atypical cadherin 1 (FAT1), KIT proto-oncogene receptor tyrosine kinase (KIT), and erb-b2 receptor tyrosine kinase 4 (ERRB4) (Fig. 1) (Table 2 ) (see Supporting Information Table 3) . 1, [7] [8] [9] [10] 12, 21 Finally, we observed a high mutation frequency in genes previously reported to be mutated in metastatic cSCC, including neurofibromin 1 (NF1) (42%), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4) (33%), and receptor interacting serine/threonine kinase 2 (RIPK2) (25%) (see Supporting Information Table 3 ). 12 
Differences in Mutation Frequency Between Paired Primary and Metastatic Samples
We were curious whether any of the mutations for which we had paired primary and metastatic samples were specific to the metastatic tumor. For the 6 primary/metastatic sample pairs, many of the mutations observed in the metastatic sample were present in the primary tumor and vice versa, but none were 100% concordant ( Fig. 1 ) (see Supporting Information Tables 3 and 4) . Two primary tumors (289199T and 387481T) for which we also sequenced a metastatic sample from the same individual did not have any mutations in common with the metastatic tumor, suggesting that they were not the cSCC giving rise to the metastasis (see Supporting Information Tables 3  and 4) . For commonly mutated genes, there was no pattern of specific genes that were found to be predominantly mutated in one type of sample versus the other, although the numbers of primary-metastatic pairs were too small to make meaningful comparisons.
Targeted Sequencing
To the best of our knowledge, no other studies to date have performed exome or targeted sequencing of primary nonmetastatic and metastatic cSCCs simultaneously. To determine whether there were differences in mutation frequency between primary nonmetastatic cSCCs and metastatic tumors, we performed targeted exon sequencing using the Ion AmpliSeq Comprehensive Cancer Panel (Thermo Fisher Scientific), which includes 409 genes. Targeted sequencing was performed rather than additional exome sequencing due to cost constraints and because this panel included the majority of the frequently mutated genes from our exome studies except for FAT1 and therefore we would be able to compare results.
Study inclusion for the targeted sequencing study was similar to our exome study. We also included one metastatic sample, 351152, for which we also performed exome sequencing. For the targeted sequencing study, more of the metastatic tumors originated from cSCCs on the face (83%) compared with the nonmetastatic primary tumors, which arose on the face (40%) or limb (50%) ( Table 1 ). There was a trend toward a younger age at the time of diagnosis in individuals with primary tumors (mean age, 62.5 years) versus individuals with metastatic tumors (mean age, 74.5 years).
For the targeted sequencing, the mean depth was 274 reads with an average of 97.91% on target reads and a uniformity of 79% (see Supporting Information Table 5 ). Gene mutation frequencies in the metastatic samples in the targeted sequencing study were similar to those in the exome study, suggesting that these 2 approaches yielded similar gene coverage (Table 2) (Fig. 2 ) (see Supporting Information Table 6 ). 1, [7] [8] [9] [10] 12, 21 Comparison of mutation frequency between metastatic samples from both studies (18 samples) and primary tumors (10 samples) demonstrated similar mutation frequencies for genes with the exception of TP53, which only had mutations in 2 of the 10 primary tumors (P 5 .02); this is much lower than Original Article previous reports for primary cSCC. This is unlikely to be due to issues with the capture technology because all 6 of the metastatic samples in the targeted study had TP53 mutations, but may be due to lower read counts for some exons. For the one individual for whom we performed exome sequencing as well as targeted sequencing for the metastatic sample (sample 351152), there was a high degree of concordance between exome and targeted sequencing data. One EP300 mutation was present at a low frequency (6% of reads) in the metastatic sample and paired primary tumor (1%) on exome analyses but was not observed in the targeted sequencing study. Of 71 missense, nonsense, and/or frameshift mutations identified by the targeted sequencing in the sample from individual 351152, 67 mutations also were detected by whole-exome analysis (94.3%). Four additional mutations were observed in the metastatic sample by both targeted and exome sequencing, but not in any reads of the primary tumor, suggesting that these either were present at very low levels in the primary tumor, were present in another part of the primary tumor not sampled, or were unique to the metastatic sample.
Comparison of Mutation Frequencies Across Exome and Targeted Sequencing Studies
Because the current study was relatively small considering the number of samples assessed, we wanted to determine how its results compared with previous exome and targeted sequencing studies. Mutation summaries for published exome-sequencing and targeted-sequencing studies of metastatic cSCC; primary nonmetastatic cSCC; and sun-exposed, histologically normal skin were evaluated for mutation frequency in genes found to be frequently mutated in our samples (Table 2) . 1, [7] [8] [9] [10] [11] [12] 21 Samples were 
Abbreviations: ND, no reported data/not included on targeted panel. a A total of 234 biopsies from 4 individuals; some overlap with regard to mutations across adjacent biopsies. b The individual sequenced using both exome and targeted sequencing was counted once for the exome sequencing. c Includes copy number aberrations.
Mutations in Metastatic and Primary SCCs/Yilmaz et al
Cancer April 1, 2017 considered to have a mutation if, compared with a matched normal DNA, the tumor had a nonsense, frameshift, missense, or splice-site mutation. We discarded nonsynonymous changes that were present in the dbSNP at a frequency of >1% unless they were reported in the COS-MIC database or other somatic mutation databases. We used the authors' cutoff values for inclusion as a mutation in their analysis, which may differ from our criteria. There was a range of reported mutation frequencies noted across the studies for some genes. For example, the frequency of samples with TP53 varied between studies from 20% in primary cSCCs in the current study to 95% of metastatic cSCCs in one series. 11 Differences between the studies may be a reflection of sample numbers, read depths, sequence analysis pipelines, or coverage of region. Overall, the mutation frequencies of genes assessed in the current study were similar to those in previous reports.
We calculated the frequency of mutations found in each gene from the 5 published studies plus data from the current study. The exact number of samples per gene varied widely depending on whether the gene was included on each study's targeted sequencing panel and whether whole-exome analyses was completed. Mutation data were available from 42 to 233 primary cSCCs and 79 to 86 metastatic cSCCs depending on the gene. Multiple genes demonstrated significant differences in mutation frequency between primary cSCCs and metastatic cSCCs after Hochberg multiple comparisons testing (Table 3) . It is interesting to note that TP53 demonstrated a significantly higher mutation frequency in metastatic tumors compared with primary tumors (85% vs 54%; P < .0001 [corrected P < .002]). This result remained significant (P < .0001) even when data from our primary tumors were removed (because they demonstrated a much lower mutation frequency than reported in the literature) or when any other study was removed from analysis. CDKN2A also demonstrated a higher mutation frequency in metastatic samples compared with primary tumors (42% vs 29%; P 5 .04), but this was not found to be significant after accounting for multiple comparisons testing, nor did this result remain significant when other studies were removed. KMT2D, a gene involved in chromatin remodeling, demonstrated a higher mutation rate in metastatic tumors, with 62% of metastatic tumors having at least 1 mutation compared with only 31% of primary tumors (P 5 .001; corrected P 5 .03). Other genes demonstrating statistically significant differences in mutation frequency included PIK3CG (7% of primary tumors vs 29% of metastatic tumors; P < .0001 [corrected P < .002]). However, this difference was totally dependent on the study by Lee et al, 10 in which exome or targeted sequencing was performed on 104 tumors, but none was found to have a PIK3CG mutation. BRAF also Figure 2 . Targeted sequencing of metastatic and primary tumor samples of cutaneous squamous cell carcinoma (cSCC). (A) The percentage of 7 metastatic samples found to have a mutation by targeted sequencing analysis of 21 commonly mutated genes is indicated (this includes sample 351152, which was exome sequenced). Genes were ranked by the percentage of samples with a potentially functional mutation (nonsense, frameshift, splice-site, or missense mutation). As indicated in the key, samples with 1 missense mutations are indicated in light red and samples with 1 truncating mutation (nonsense or frameshift mutation) are indicated in dark red. (B) The percentage of 10 primary cSCCs found to have a mutation in 1 of 21 commonly mutated genes by targeted sequencing is indicated. Genes were ranked by the percentage of samples with a potentially functional mutation (nonsense, frameshift, splice-site, or missense mutation). As denoted in the key, samples with 1 missense mutations are indicated in light blue and samples with 1 truncating mutation (nonsense or frameshift mutation) are indicated in dark blue. demonstrated borderline differences (5% of primary tumors vs 13% of metastatic tumors; P 5 .04). There were more FAT1 mutations observed in primary tumors (37%) compared with metastatic tumors (22%), but this was not found to be statistically significant after adjusting for multiple comparisons or when other studies were removed from analysis. The DNA repair gene ATR demonstrated a trend toward a difference, being mutated in 6 of 42 primary tumors (14%) versus 25 of 86 metastatic cSCCs (29%) (P 5 .08).
DISCUSSION
Herein, we present data from whole-exome and/or targeted sequencing for 18 metastatic cSCCs and 10 primary nonmetastatic cSCCs. Findings from the current study are consistent with previous exome analyses of SCCs: TP53, NOTCH pathway genes, CDKN2A, phosphoinositide-3-kinase (PI3K)/AKT pathway genes, and epigenetic regulators were mutated at high rates in both nonmetastatic primary samples and metastatic samples.
Primary tumors giving rise to metastases demonstrated a high concordance of gene mutations, with the metastatic sample suggesting that many mutations are occurring before metastasis. The concept of mutations occurring early in skin tumor development is consistent when comparing primary tumor results with those of histologically normal, sun-exposed skin; genes demonstrating frequent mutations in the primary tumors, including TP53, NOTCH1 epigenetic regulators, and DNA repair genes, have been found previously in a substantial percentage of samples of histologically normal, sun-exposed skin. 9, 21 We identified multiple genes with differential mutation frequencies between metastatic and nonmetastatic primary tumors. It is interesting to note that TP53, a highly characterized gene in cSCC, demonstrated a statistically higher rate of mutation in metastatic tumors (85%) compared with primary nonmetastatic cSCCs (54%). Further studies are needed to understand the implications of this finding.
Genes important in chromatin remodeling and histone modification demonstrated high rates of mutations across all samples, but only KMT2D demonstrated significantly higher rates of mutation in the metastatic tumors (62%) compared with nonmetastatic tumors (31%). KMT2D is a histone methyltransferase that regulates H3 lysine 4 and is mutated in other cancers such as cutaneous melanoma (19%-29%), esophageal SCC (14%-19%), and SCC of the head and neck (11%-16%). 19, 20, [22] [23] [24] [25] [26] KMT2D-mutated cells in vitro demonstrate increased transcriptional stress and genomic instability. 27 Other epigenetic regulators (EP300, SETD2, KMT2C, KMT2D, KDM6A, and KDM6B) are mutated in a variety of SCCs of the lung, esophagus, and head and neck, suggesting that common epigenetic pathways drive squamous cell carcinogenesis, and these also may correlate with tumor aggressiveness. 13, 22, [28] [29] [30] A previous study of 39 metastatic cSCCs identified KMT2C mutations in approximately 69% of tumors that were highly correlated with bone metastasis. 11 Approximately 67% of metastatic samples in the current study were found to have mutations in this gene, but there were no significant differences in KMT2C mutation frequency observed between nonmetastatic primary and metastatic tumors across the published studies. CREBBP is a transcriptional coactivator, with a high degree of similarity to p300, which couples chromatin remodeling with transcription factor recognition and has histone acetyltransferase activity. 31 In previous studies, approximately 35% to 36% of primary cSCCs had CREBBP missense mutations, but it was not clear whether these were functional. 9, 32 We observed CREBBP mutations in 28% of metastatic samples and 40% of primary tumors in the current study (Table 2) , 1, [7] [8] [9] [10] [11] [12] 21 but observed no significant differences between metastatic and nonmetastatic cSCCs from published studies (Table 3) , suggesting similar mutation frequencies in metastatic and nonmetastatic tumors. Collectively, these studies suggest that mutations in some epigenetic and chromatin regulators may be associated with metastatic cSCC and that, generally, epigenetic pathways are a common mutational target in cSCC.
KNSTRN previously was found to be mutated in 19% of cSCCs. 10 It is interesting to note that we did not observe mutations in KNSTRN. To ensure that we were not missing any mutations in our exome analyses, we specifically examined our genomic coverage in this region and BAM file sequences. We had an average read depth of 330 to 3 50 for exons of this gene, including the "hotspot" mutation, but did not identify any KNSTRN mutations. This could be due to different mutation profiles between nonmetastatic and metastatic cSCCs or due to the smaller number of samples in the current study. The data from the current study are consistent with those of other studies of metastatic cSCCs that did not identify any mutations in KNSTRN.
12
One difference between the current study and previous reports is the inclusion of 6 matched primary and normal DNA samples for the analyses and the high level of mutation concordance noted between these related tumors. The high concordance rate observed between the paired primary and metastatic samples suggests that the exome sequencing data had high sensitivity for detecting mutations. The power of this study and the current study findings was increased by incorporating data from 5 additional studies. For many of the genes, the mutation rate in the current study samples was similar to that of previous studies. It is interesting to note that data from the current study are similar to cSCC mutation data in mice. Two studies recently performed whole-exome sequencing on primary and metastatic tumors in mice. 33, 34 Although some of the murine tumors were induced by chemicals instead of ultraviolet light, many of the same genes mutated in the samples in the current study were shown to be mutated in the metastatic mouse cSCCs, including Trp53 (30%), Notch1 (30%), Kmt2c (26%), Kmt2d (22%), and Fat1 (19%). 33 There are limitations to the current study, which include the small number of samples sequenced in our series. Thus, we may be missing mutations that are meaningful in a small subset of samples or in genes that are underrepresented. In addition, the current study did not assess for copy number changes. Because CDKN2A demonstrates a high degree of copy number loss in cSCCs, this may explain the relatively low mutation rate noted in this gene in the current study. 12 Another limitation is that histologically normal adjacent tissue was used for 10 of the 18 metastatic cases as a source of normal DNA. Studies have shown a high degree of mutation in histologically normal sunexposed skin. 9, 21 Thus, somatic mutations present in >9% of reads in both the adjacent paired normal and tumor samples would not have been identified due to our variant filtering process. It has been well established that tumors are highly heterogeneous; because we sampled only a portion of the tumor, we may be missing mutations unique to other parts of the tumor. Only 1 sample in the current series was sequenced by both exome and targeted sequencing and therefore it is difficult to directly compare the sensitivity and specificity of the 2 approaches. However, for that sample, there was a high degree of concordance (94%) for the targeted sequencing compared with the exome data. Finally, there are limitations to aggregating data from multiple independent studies because there are differences in variant-calling pipelines, including the number of reads required to "call" a mutation and read depths. This was evident by the statistically significant differences in PIK3CG mutation rates being driven by one study. Further studies also are important to confirm the findings noted in the current study, particularly the genes demonstrating borderline differences in mutation frequency. Studies to determine the functional role of mutations in these genes in metastasis also are warranted.
In summary, exome and targeted sequencing of 18 metastatic cSCCs and 10 primary tumors and a pooled analysis of other studies consisting of up to 223 cSCCs and 68 metastatic cSCCs revealed frequent mutations in genes important for chromatin remodeling, DNA repair, and the PI3K/AKT pathway. Analyses demonstrated that KMT2D and TP53 had higher mutation frequencies in the metastatic cSCC samples compared with nonmetastatic cSCC. Future studies are needed to dissect the biological relevance of these mutations in aggressive phenotypes in order to identify biomarkers that predict metastasis and potentially lead to new therapeutic targets.
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